Takeda submits IBD drug candidate for FDA approval

06/25/2013 | PharmaTimes (U.K.)

Takeda Pharmaceutical has filed a biologics license application with the FDA for approval to use its experimental monoclonal antibody drug vedolizumab as a treatment for moderately to severely active Crohn's disease and ulcerative colitis. The application was based on data from four late-stage international trials involving 2,700 patients.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX